^
    Contact us  to learn more about
    our Premium Content:  News alerts, weekly reports and conference planners
    DRUG:

    Yidafan (ivonescimab)

    i
    Other names: AK112, AK 112, AK-112, SMT112, SMT-112, SMT 112
    Company:
    Akesobio, Summit Therapeutics
    Drug class:
    PD1 inhibitor, VEGF inhibitor
    Related drugs:
    3d
    Observational Study of Objective Response Rate to Ivonescimab Combined with Chemotherapy in Patients with Locally Advanced Resectable Oral and Oropharyngeal Squamous Cell Carcinoma (ChiCTR2600117410)
    P=N/A, N=20, Not yet recruiting, Zhujiang Hospital of Southern Medical University; Zhujiang Hospital of Southern Medical University
    New trial
    |
    Yidafan (ivonescimab)
    3d
    Ivonescimab combined with chemotherapy treated with recurrent/persistent ovarian, fallopian tube, or primary peritoneal clear cell carcinoma patients：a single arm, open-label , single center exploratory study (ChiCTR2600115984)
    P=N/A, N=20, Not yet recruiting, West China Second Hospital of Sichuan University; West China Second Hospital of Sichuan University
    New trial
    |
    carboplatin • gemcitabine • albumin-bound paclitaxel • Yidafan (ivonescimab)
    3d
    Prospective, Single-Center, Single-Arm Clinical Study of Ivosidenib (AK112) Combined with Chemotherapy for Neoadjuvant Treatment of Locally Advanced Oral Squamous Cell Carcinoma (ChiCTR2600117076)
    P4, N=15, Not yet recruiting, The first affiliated hostipal of nanchang university; The first affiliated hostipal of nanchang university
    New P4 trial
    |
    carboplatin • paclitaxel • docetaxel • pemetrexed • Tibsovo (ivosidenib) • Yidafan (ivonescimab)
    3d
    AK112 (Ivosimlimab) in combination with chemotherapy as first-line treatment for recurrent or advanced endometrial cancer (ChiCTR2500111544)
    P4, N=50, Not yet recruiting, Zhejiang Cancer Hospital; Zhejiang Cancer Hospital
    New P4 trial
    |
    Yidafan (ivonescimab)
    3d
    A Study of Ivonescimab Plus Neoadjuvant Chemotherapy Followed by Chemoradiotherapy for High-Risk Locally Advanced Cervical Cancer (ChiCTR2600115927)
    P2, N=42, Not yet recruiting, Women’s Hospital, Zhejiang University School of Medicine; Women’s Hospital, Zhejiang University School of Medicine
    New P2 trial
    |
    PD-L1 (Programmed death ligand 1)
    |
    cisplatin • paclitaxel • Yidafan (ivonescimab)
    3d
    A Single-Arm, Multicenter Clinical Study of Eribulin Mesylate in Combination with Ivonescimab as First-Line Treatment for Unresectable Locally Advanced or Metastatic Triple-Negative Breast Cancer (ChiCTR2600117652)
    P2, N=50, Not yet recruiting, Sir Run Run Shaw Hospital, School of Medicine, Zhejiang University; Sir Run Run Shaw Hospital, School of Medicine, Zhejiang University
    New P2 trial
    |
    HER-2 (Human epidermal growth factor receptor 2) • PGR (Progesterone receptor)
    |
    HER-2 negative • ER negative
    |
    Halaven (eribulin mesylate) • Yidafan (ivonescimab)
    6d
    Huaxi: Perioperative Ivonescimab Plus S-1 and Oxaliplatin (SOX) for Locally Advanced Gastric or GEJ Adenocarcinoma (clinicaltrials.gov)
    P2, N=154, Not yet recruiting, Sichuan University
    New P2 trial
    |
    oxaliplatin • Teysuno (gimeracil/oteracil/tegafur) • Yidafan (ivonescimab)
    7d
    PrE0510: Phase II Study of Platinum/Etoposide Plus Ivonescimab for Extensive-Stage Small Cell Lung Cancer (clinicaltrials.gov)
    P2, N=60, Recruiting, PrECOG, LLC. | Not yet recruiting --> Recruiting
    Enrollment open
    |
    carboplatin • etoposide IV • Yidafan (ivonescimab)
    11d
    Ivonescimab and ADG126, Alone, and in Combination With Leucovorin and Fluorouracil or FOLFIRI Regimen for the Treatment of Microsatellite Stable Advanced/Metastatic Colorectal Cancer (clinicaltrials.gov)
    P1, N=30, Not yet recruiting, City of Hope Medical Center
    New P1 trial
    |
    CD4 (CD4 Molecule)
    |
    irinotecan • leucovorin calcium • Yidafan (ivonescimab) • fluorouracil topical • muzastotug (ADG126)
    11d
    COLIBRI-GI: Testing Ivonescimab in Combination With Chemotherapy in Patients With Metastatic Colorectal Cancers Without Liver Metastases (clinicaltrials.gov)
    P2, N=130, Not yet recruiting, UNICANCER
    New P2 trial • Mismatch repair • pMMR
    |
    BRAF (B-raf proto-oncogene)
    |
    BRAF wild-type
    |
    Avastin (bevacizumab) • 5-fluorouracil • irinotecan • leucovorin calcium • Yidafan (ivonescimab)
    12d
    Mechanism of Enhanced Efficacy of Ivonescimab in Neoadjuvant Therapy for Non-Small Cell Lung Cancer (clinicaltrials.gov)
    P=N/A, N=200, Not yet recruiting, Peking University People's Hospital
    New trial
    |
    Yidafan (ivonescimab)
    13d
    AK112-309: AK112 Combined With Chemotherapy Versus Durvalumab Combined With Chemotherapy in Advanced Biliary Tract Cancer (clinicaltrials.gov)
    P3, N=682, Active, not recruiting, Akeso | Trial primary completion date: Jul 2027 --> Oct 2026 | Not yet recruiting --> Active, not recruiting
    Enrollment closed • Trial primary completion date
    |
    cisplatin • Imfinzi (durvalumab) • gemcitabine • Yidafan (ivonescimab)